PT - JOURNAL ARTICLE AU - Patel, Areeba AU - Dogan, Helin AU - Payne, Alexander AU - Sievers, Philipp AU - Schoebe, Natalie AU - Schrimpf, Daniel AU - Stichel, Damian AU - Holmes, Nadine AU - Euskirchen, Philipp AU - Hench, Jürgen AU - Frank, Stephan AU - Rosenstiel-Goidts, Violaine AU - Ratliff, Miriam AU - Etminan, Nima AU - Unterberg, Andreas AU - Dieterich, Christoph AU - Herold-Mende, Christel AU - Pfister, Stefan M AU - Wick, Wolfgang AU - Schlesner, Matthias AU - Loose, Matthew AU - von Deimling, Andreas AU - Sill, Martin AU - Jones, David TW AU - Sahm, Felix TI - Rapid-CNS<sup>2</sup>: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study AID - 10.1101/2021.08.09.21261784 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.09.21261784 4099 - http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261784.short 4100 - http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261784.full AB - Background The 2021 WHO classification of central nervous system tumors includes multiple molecular markers and patterns that are recommended for routine diagnostic use in addition to histology. Sequencing infrastructures for complete molecular profiling require considerable investment, while batching samples for sequencing and methylation profiling can delay turnaround time. We introduce RAPID-CNS2, a nanopore adaptive sequencing pipeline that enables comprehensive mutational, methylation and copy number profiling of CNS tumours with a single, cost-effective sequencing assay. It can be run for single samples and offers highly flexible target selection that can be personalized per case with no additional library preparation.Methods Utilizing ReadFish, a toolkit enabling targeted nanopore sequencing without the need for library enrichment, we sequenced DNA from 22 diffuse glioma samples on a MinION device. Target regions comprised our Heidelberg brain tumor NGS panel and pre-selected CpG sites for methylation classification using an adapted random forest classifier. Pathognomonic alterations, copy number profiles, and methylation classes were called using a custom bioinformatics pipeline. The resulting data were compared to their corresponding standard NGS panel sequencing and EPIC methylation array results.Results Complete concordance with the EPIC array was found for copy number profiles. The vast majority (94%) of pathognomonic mutations were congruent with standard NGS panel-seq data. MGMT promoter status was correctly identified in all samples. Methylation families from the random forest classifier were detected with 96% congruence. Among the alterations decisive for rendering a WHO 2021 classification-compatible integrated diagnosis, 97% of the alterations were consistent over the entire cohort (completely congruent in 19/22 cases and sufficient for unequivocal diagnosis in all 22 samples).Conclusions RAPID-CNS2 provides a swift and highly flexible alternative to conventional NGS and array-based methods for SNV/InDel analysis, detection of copy number alterations, target gene methylation analysis (e.g. MGMT) and methylation-based classification. The turnaround time of ∼5 days for this proof-of-concept study can be further shortened to &lt; 24h by optimizing target sizes and enabling real-time computational analysis. Expected advances in nanopore sequencing and analysis hardware make the prospect of integrative molecular diagnosis in an intra-operative setting a feasible prospect in future. This low-capital approach would be cost-efficient for low throughput settings or in locations with less sophisticated laboratory infrastructure, and invaluable in cases requiring immediate diagnoses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Deutsche Forschungsgemeinschaft (DFG) via Comprehensive Research Center (SFB) 1389 Unite Glioblastoma.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval 2018-614N-MA, 005/2003 at University Heidelberg Ethics Committee I and IIAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata will be made available upon reasonable request